superthesis × polymarketmarket watch · 05
calendar beats the science here
The crowd puts this at 12%.
Our read lands at half that.
Retatrutide's Phase 3 results are historically strong — up to 30.3% mean body-weight reduction in TRIUMPH-1, the largest ever recorded in a pharmacological trial. The bottleneck is not the science; it is a sequential procedural calendar that cannot compress to fit inside 2026.
A price tells you what people bet. A verdict tells you why.
analysis as of Jun 24, 2026 · crowd price as of Jun 24, 2026
/ the questionmarket snapshot · Jun 24, 2026
/ what the market is pricing
One claim. Real money on the line.
Polymarket crowd · Jun 24, 2026
12%
implied probability · yes
0 · nolong shotyes · 100
/ superthesis · run on the same claimthe engine, not the odds
/ argue both sides, score the evidence
What the engine actually finds.
“FDA approves Retatrutide this year?”
The crowd prices retatrutide's 2026 FDA approval at 12%; after arguing both sides, superthesis lands at 6% — the regulatory clock alone makes a same-year approval arithmetically unreachable under any standard pathway.
TRIUMPH-1 and TRIUMPH-4 phase 3 efficacy data complete and NDA-ready for obesity indication
clearedEli Lilly NDA submission to FDA — reaffirmed for Q4 2026, not yet filed as of June 2026
openNDA filed early enough for 60-day acceptance window plus 6-month Priority Review to conclude by Dec 31, 2026
refutedExpedited FDA designation (Breakthrough Therapy, Fast Track, or Priority Review) confirmed — none granted as of June 2026
refutedPDUFA action date on or before December 31, 2026 — no date exists; earliest plausible date is Q2 2027
refutedThesis · the case for
TRIUMPH-1 and TRIUMPH-4 delivered the strongest Phase 3 weight-loss data ever recorded — up to 30.3% mean body-weight reduction — and Eli Lilly reaffirmed a Q4 2026 NDA submission target on its Q1 2026 earnings call, leaving a theoretical residual probability for extraordinary, non-standard FDA action. The efficacy case for a Priority Review designation, once filed, is unusually strong given the tirzepatide obesity precedent.
Antithesis · the case against
No NDA has been submitted as of June 2026, no PDUFA date exists, and the sequential FDA clock — a 60-day acceptance window followed by a minimum 6-month Priority Review — applied to any Q4 2026 filing produces an earliest approval date of approximately Q2 2027. No rolling submission, emergency authorization precedent in the obesity indication, or accelerated pathway mechanism has been disclosed by Eli Lilly or the FDA.
Synthesis · the calibrated reading
The claim that the FDA will approve retatrutide in 2026 is refuted with high confidence on procedural grounds that are uncontested by either argument. While retatrutide's Phase 3 efficacy data (−28.3% to −30.3% body weight reduction across TRIUMPH-1 and TRIUMPH-4) is genuinely unprecedented and NDA-ready for the obesity indication, no NDA has been filed as of June 2026, no expedited designation has been granted, and the sequential FDA review clock — at minimum 6 months from NDA acceptance under Priority Review, plus a 60-day acceptance window — makes a December 31, 2026 approval date arithmetically impossible under any standard regulatory pathway. Both opposing arguments independently…
0.06superthesis signal
0.03–0.09
0.03–0.09
0 · refutedcontestedconfirmed · 1.0
// the cases, gates, and the calibrated signal are from a live superthesis run on this claim. every source it weighed is listed below.
/ the evidenceevery claim, sourced
/ what the verdict is built on
The receipts. No black box.
superthesis cites what it reads. These are the sources weighed in the run above — open and auditable.
01Eli Lilly Investor Relations — TRIUMPH-4 Press Release, December 11, 2025.02Eli Lilly / PR Newswire — TRIUMPH-1 Press Release, May 21, 2026.03AJMC — Retatrutide Achieves Up to 30.3% Average Weight Loss in Phase 3 TRIUMPH-1 Trial, 2004Lilly Medical Affairs — TRIUMPH-4 Q&A, 2025.05PharmExec — Lilly's Retatrutide Displays Positive Topline Results in Successful Phase III 06FindHonestCare.com — Retatrutide FDA Approval Timeline & Status 2025–2027, 2026.07SEC.gov — Eli Lilly Form 8-K FY2026 Q1 Earnings.08Eli Lilly Investor Relations — TRIUMPH-1 Press Release, May 21, 2026.09RetaWeightLoss.com — Retatrutide FDA Approval Status: June 2026 Update.10PR Newswire / Eli Lilly — Lilly to present new data at ADA's 86th Scientific Sessions, 20211Drugs.com — Retatrutide: What is it and is it FDA approved? (Regulatory drug database), 2012Eli Lilly — What to know about retatrutide (official page), 2026.13RetaWeightLoss.com — When Will Retatrutide Be FDA Approved? 2026 Timeline Update.14Pharmaceutical Executive (PharmExec) / Clarivate — Lilly's Orforglipron, Retatrutide Named15Retatruti.de — Retatrutide Phase 3 TRIUMPH Trials Completion Dates — May 2026 Impact on ND
/ crowd vs. enginea price is not an argument
/ why this matters
The market gives you a number.
We give you the reasoning.
DisagreesWe read 6 pts lower than the crowd, so we agree on the call, but not the confidence. On conviction, our stance is more resolute — 5 pts further from a coin-flip.
/ same claim · two ways of knowing
Polymarket · 0.12
superthesis · 0.06
0 · won't happen1.0 · will happen
A prediction market aggregates bets; superthesis aggregates arguments — it decomposes the claim, makes the strongest case on each side from sourced evidence, and reports a calibrated reading you can audit. The price says where the crowd sits; the verdict shows why.
/ what $1,000 does · Polymarket order book · reviewed Jun 23, 2026
Our call
No the outcome our reading favors
$1,000 returns if our call is right
$1,102 profit $102
Market price vs our read
91¢ market · we read 94¢ — we read our call cheaper than the market
Expected value if our read is right
+$35position worth ~$1,035 — above the $1,000 stake
Illustrative only — not financial advice and not a recommendation to bet. The return is the live Polymarket order-book total for a $1,000 position on our call, reviewed Jun 23, 2026; the “expected value” assumes our calibrated reading is the true probability — exactly what’s uncertain. Prices move; the live market is linked above.
/ since we called itthe record, live
/ has the crowd moved our way since Jun 23, 2026?
Since we called it — where the crowd went.
Our reading · Jun 23, 2026
0.06
Crowd · Jun 23, 2026
12%→
Crowd · Jul 17, 2026
9%
our read 0.06
then
now
0 · won’t happen1.0 · will happen
The crowd has since moved 3 pts toward our reading.
// live Polymarket price, keyed to this market’s id and re-fetched when you load the page. “Toward” on an open market means the crowd has drifted our way — suggestive, not proof; being early isn’t being right until it resolves.
Stop reading the odds. Read the evidence.
Point superthesis at any claim, market, or question — and watch it argue both sides, cite every source, and resolve a calibrated signal. Free while The Field is in early access.